Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $22.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reiterated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $24.67.

Stoke Therapeutics Stock Performance

STOK stock opened at $7.02 on Wednesday. The stock has a fifty day moving average of $8.28 and a 200-day moving average of $10.52. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The company has a market capitalization of $379.63 million, a price-to-earnings ratio of -3.34 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock valued at $143,332. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares during the last quarter. Graham Capital Management L.P. raised its stake in shares of Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after acquiring an additional 1,453 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Stoke Therapeutics by 2.0% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after acquiring an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.